Fig. 4: mKRAS T cell response correlates to tumor biomarker response and delayed tumor recurrence.

a, OS from study start (date of first vaccine dose), n = 25; n indicates individual patients. b, Best overall tumor biomarker response for study participants reported as percentage of the baseline value, stratified by T cell response (maximum fold change from baseline; ≥ median versus < median), n = 25. P value was calculated by two-tailed Mann–Whitney test. c, RFS from study start (date of first vaccine dose), n = 25; n indicates individual patients. Values depicted are mean ± s.d. d, RFS from study start (date of first vaccine dose) stratified by T cell response (maximum fold change from baseline; ≥median versus <median), n = 25; n indicates individual patients. HR indicates hazard ratio with 95% CI. P values were calculated using two-tailed log-rank test.